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Abstract
Metastasis is the leading cause of cancer-associated deaths. While dissemination of tumor cells 
likely occurs early in tumorigenesis, the constituents of the microenvironment play essential rate-
limiting roles in determining whether these cells will form clinically-relevant tumors. Recent 
studies have uncovered many molecular factors that contribute to establishment of a pro-
tumorigenic metastatic niche. Here, we demonstrate that galectin-3, whose expression has clinical 
associations with advanced malignancy and poor outcome, contributes to metastatic niche 
formation by binding to carbohydrates on metastatic cells. We show that galectin-3 is expressed 
early during tumorigenesis by both CD11b+Gr-1+ and CD11b+Ly-6Chi leukocytes. Tumors 
mobilize these myeloid populations through secretion of soluble factors including IL-6. We find 
that metastatic cancer cells exhibit elevated presentation of the oncofetal galectin-3 carbohydrate 
ligand, the Thomsen-Friedenreich Antigen, on their surfaces as a result of altered C2GnT2 and 
St6GalNAcIV glycosyltransferase activity that inhibits further glycosylation of this carbohydrate 
motif and promotes metastasis.
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Introduction
Galectins are a family of β-galactoside binding lectins whose pleiotropic roles in 
tumorigenesis have been reported to range from interactions with oncoproteins, to 
immunomodulation, to promotion of angiogenesis, to eliciting anti-apoptotic effects through 
BCL2 homologies (1–3). Despite the fact that galectins lack a signal sequence or 
transmembrane domain, they can be incorporated into the extracellular matrix (ECM), 
secreted as soluble factors into circulation, presented on cell surfaces, or act intracellularly. 
In particular, the presence of galectin-3 as an extracellular molecule (circulating in serum or 
localized on cells within tissues) has been associated with metastasis. Elevated levels of 
galectin-3 have been reported in patients with advanced stages of a variety of cancers (4, 5), 
and treatment of mice bearing xenograft tumors with a truncated form of the protein that acts 
as a competitive binding inhibitor has been reported to reduce incidences of metastases (6). 
In particular, galectin-3 and galectin-8 contain carbohydrate recognition domains (CRDs) 
that exhibit specific affinities for the oncofetal core 1 O-linked disaccharide termed the 
Thomsen-Friedenreich Antigen (T-Antigen) (7–9). While this mucin-type glycan motif 
forms the core structure of most O-glycans (Galβ1-3GalNAcα1-Ser/Thr), exposure of the 
disaccharide form is generally occluded by further glycosylation. It is estimated, however, 
that the cells in as many as 90% of carcinomas express this disaccharide without further 
glycosylation (10). Nonetheless, the mechanisms by which this conserved glycan motif is 
regulated by cancer cells, along with the precise role that it plays in tumorigenesis and 
metastasis, are poorly understood.
Recently, the role that dynamic remodeling of the tumor microenvironment plays in the 
promotion of metastasis has been partially elucidated (11–13). Soluble factors released from 
tumors act to mobilize bone marrow-derived cells (BMDCs), and in particular myeloid cells, 
into the peripheral blood and recruit them to the early metastatic niche, a site where 
metastases have yet to reach a detectable size. Frequently, these myeloid cells consist of 
CD11b+ cells that are Ly-6Chi or Gr-1+. The former population typically consists of 
inflammatory monocytes, while the latter may represent neutrophils or a heterogeneous 
poorly differentiated granulocyte population that exhibits suppressor functions, sometimes 
referred to as myeloid-derived suppressor cells (MDSCs). Crosstalk between primary or 
metastatic tumors and these or other non-parenchymal populations induce the secretion of 
factors in autocrine, paracrine, and endocrine fashions in a manner that promotes remodeling 
of the primary tumor, bone marrow, and metastases to promote malignant progression. 
Among the molecules that are involved in metastatic niche formation, many are extracellular 
matrix (ECM) molecules and their modifiers including fibronectin, collagen IV, tenascin-c, 
osteopontin, periostin, versican, lysyl oxidase (LOX), and a variety of matrix 
metalloproteinases (MMPs) (14–21). The role of cell-surface galectins, however, as 
components of the early metastatic niche, remains to be investigated.
Alterations in gene expression, cytokine secretion, and ECM and soluble factor production 
have all been associated with improved interactions between metastatic cells and specific 
microenvironments (14–16, 18, 19, 22–26). To determine the involvement of galectin-3 
within the metastatic niche and of aberrant glycosylation of cancer cell-associated surface 
glycoproteins, we used a mouse model of lung adenocarcinoma metastasis (27–29). 
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Previously, we used our ECM microarray platform to identify adhesion ligands associated 
with metastasis and identified galectin-3 and -8 as exhibiting preferential adhesion to 
metastatic cells (30). Here, we identify galectin-3 as a component of the metastatic niche 
through expression on myeloid cells. We find that changes in glycosylation by the cancer 
cells mediate their increased interactions with galectins, and that these alterations play 
essential roles in conferring metastatic potential. In particular, we find that the upregulation 
of the sialyltransferase St6GalNAcIV and downregulation of the core 2 N-
acetylglucosaminyltransferase C2GnT2 (Gcnt3) are key mediators of the changes in 
glycosylation that potentiate metastatic proclivity by preserving presentation of the T-
Antigen.
Results
Tumor-bearing mice exhibit elevated levels of galectin-3 in the early metastatic niche
To determine the role of galectin-3 in metastasis, we used a genetic mouse model of lung 
adenocarcinoma metastasis (KrasLSL-G12D/+;p53flox/flox) from which cell lines representing 
distinct stages of metastatic progression were derived(27–29). Following Cre-mediated 
recombination and the development of autochthonous lung tumors and metastases, lines 
were generated from primary tumors that did not give rise to metastases (TnonMet), did give 
rise to metastases (TMet), lymph node metastases (N), and liver metastases (M). Previously, 
we found that increasingly metastatic lines exhibited increased adhesion to galectin-3 in 
vitro (Fig. 1A) (30). As ECM molecules and their modification by BMDCs play important 
roles in the development of the metastatic niche, we asked whether galectin-3 has a role in 
its establishment. Livers were harvested from tumor-bearing mice prior to the detection of 
overt metastases, and examined for accumulation of galectin-3. Western blot analysis of 
liver protein lysates revealed an elevation in galectin-3 in the livers of tumor-bearing mice 
compared to naïve mice (Fig. 1B). To identify the source of this galectin, we examined both 
the tumor cells and recruited leukocytes. Gene expression microarray and western blot 
analyses of galectin-3 in the tumor cell lines revealed equivalent expression of the molecules 
across all four classes of lines, indicating that galectin-3 expression by tumors is not 
differentially regulated during tumor progression (Supplementary Fig. 1A, B). In light of 
recent reports of myeloid-derived populations supporting outgrowth of metastatic tumors, 
however, we asked whether such populations might also be presenting galectin-3 within the 
early metastatic niche. Staining for macrophages and galectin-3 in liver sections of mice 
bearing either TnonMet or M tumors but no detectable overt metastases revealed 
colocalization of galectin-3 with F4/80pos macrophages (Fig. 1C). While galectin-3pos 
macrophages are present in the livers of tumor-free mice as well, their numbers are two to 
four times lower than observed in tumor-bearing mice (Fig. 1C). Furthermore, 
immunostaining of the engrafted tumors also revealed a dense macrophage infiltration that 
colocalized with galectin-3 staining (Supplementary Fig. 1C). While other sources of 
galectin-3 could include secretion directly by the tumors, these findings suggested the 
possibility that leukocytes might be expressing galectin-3, themselves.
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Tumor-bearing mice exhibit circulating CD11b+galectin-3+ myeloid cells early in 
tumorigenesis
Given our observation of galectin-3 expressing macrophages in the metastatic niche, we 
asked whether tumors induce the mobilization of leukocytes expressing galectin-3. We 
harvested peripheral blood from naïve mice or mice bearing tumors generated by either 
TnonMet or M lines (Supplementary Fig. 2A–C) and analyzed it for the presence of 
galectin-3+ and CD11b+ myeloid cells. Analysis of peripheral blood cells by flow cytometry 
revealed a marked increase in galectin-3+ and CD11b+ leukocytes in the circulation of mice 
bearing both the M and TnonMet tumors (Fig. 2A–C and Supplementary Fig. 2D–F). 
Consistent with the findings of galectin-3+ macrophages in the liver, there was an 
enrichment in galectin-3+CD11b+ double-positive populations in the blood of tumor-bearing 
mice (Fig. 2A,D). In agreement with previous reports of increases in inflammatory myeloid 
cells in tumor-bearing mice, there was a significant increase in the frequency of 
CD11b+Gr-1+ and CD11b+Ly-6Chi populations (Fig. 2E,F and Supplementary Fig. 2G,H), 
which may represent neutrophils or MDSCs and inflammatory monocytes (IMs), 
respectively, with the latter population being CD115+ (Supplementary Fig. 2I). Comparisons 
of the galectin-3 levels on the CD11b+Ly-6Chi and CD11b+Ly-6Clo populations reveal 
three- to four-fold higher expression on the enriched population (Fig. 2G). In contrast, 
galectin-3 levels on the various subpopulations of CD11b+ leukocytes were not affected by 
the presence of tumors (Supplementary Fig. 3A–C), suggesting that there is increased 
mobilization of multiple galectin-3+ populations into the circulation rather than increased 
expression on individual leukocytes.
Galectin-3 has been reported to bind a variety of macrophage cell-surface glycoproteins 
(31). To determine whether the galectin-3 is bound to leukocytes through carbohydrate 
interactions or is presented in a manner that still permits interactions with the carbohydrate 
recognition domain (CRD), we isolated CD11b+ cells from the blood of tumor-bearing mice 
and incubated them in the presence of a competitive galectin-3 ligand, lactose, or a control, 
sucrose. Subsequent analysis revealed no significant difference in galectin-3 binding 
suggesting that galectin-3 is presented on the surfaces of these populations in a 
carbohydrate-independent manner, thus preserving the availability of the CRD to interact 
with other glycan ligands (Supplementary Fig. 4). Taken together, these data support the 
hypothesis that the presence of tumors induces the mobilization of CD11b+galectin-3+ 
myeloid-derived cells to the blood and that these leukocytes present galectin-3 in a manner 
that permits additional carbohydrate interactions with the lectin.
Tumor-derived interleukin 6 mobilizes CD11b+galectin-3+ leukocytes into the peripheral 
blood
Tumor-derived soluble factors frequently induce the mobilization and recruitment of pro-
metastatic CD11b+ populations (17, 19, 20, 25, 26, 32). To determine whether tumor-
secreted factors were responsible for the observed mobilization of CD11b+galectin-3+ 
populations, we collected conditioned media (CM) from the cell lines and injected it into the 
circulation of wild-type mice. Two hours following injection of the CM, we harvested 
peripheral blood and analyzed the populations by flow cytometry. This analysis revealed 
pronounced increases in circulating CD11b+galectin-3+ leukocytes and relevant 
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subpopulations (Fig. 3A and Supplementary Fig. 5A–D). Again, differences in the level of 
galectin-3 expression on individual cells were not detectable in the peripheral blood between 
the two conditions (Supplementary Fig. 5E), suggesting that the elevated galectin-3 levels 
were due to increased mobilization of galectin-3+ populations rather than increased 
expression of galectin-3 by the mobilized leukocytes.
Soluble galectin-3 has been reported to act as a chemoattractant for macrophages, 
monocytes, and neutrophils(1, 33, 34). The galectin-3 that we have observed has primarily 
been presented on the surfaces of leukocytes (Fig. 1C and 2). As the tumors also secrete 
galectin-3, however, we asked whether galectin-3 itself is capable of inducing the rapid 
mobilization of CD11b+galectin-3+ leukocytes. Injections of recombinant murine galectin-3 
in control medium, however, failed to elicit any increased mobilization of the 
CD11b+galectin-3+ populations (Fig. 3A and Supplementary Fig. 5). Nonetheless, it is 
possible that galectin-3 might act in combination with other secreted factors to mobilize 
these populations. To determine whether galectin-3 is necessary to induce mobilization, we 
knocked down galectin-3 in the M line using short hairpins (Supplementary Fig. 6A). While 
this knockdown reduced the CM concentrations of galectin-3 by approximately 80%, there 
was no observable difference in the mobilization of any of the galectin-3+ leukocytes or 
their surface levels of galectin-3 (Fig. 3B and Supplementary Fig. 6B–F). Furthermore, mice 
bearing tumors formed by the knockdown lines exhibited no differences in circulating 
galectin-3+ leukocytes in the peripheral blood or the number of galectin-3posF4/80pos 
macrophages in their livers (data not shown and Supplementary Fig. 6G). Taken together, 
these data suggest that tumor-derived galectin-3 has no effect on the mobilization of 
galectin-3+ leukocytes or their presentation of galectin-3, nor does it act in an autocrine 
fashion on tumor cells to induce secretion of other inflammatory cytokines.
While galectin-3 does not affect mobilization of leukocytes, we asked whether its expression 
by metastatic cells is necessary for seeding or colonization. To determine whether tumor-
derived galectin-3 acts in a cell-autonomous manner to support growth of disseminated 
tumor cells, we performed experimental metastasis assays with the galectin-3 knockdown 
lines. Two weeks following intrasplenic inoculation of tumor cells, we queried mice for 
hematogenous dissemination to the liver and subsequent colonization. Analysis of GFP+ 
tumor nodules on livers of mice injected with the M cell line containing the shRNAs 
revealed no differences in metastasis formation between the control hairpin (shLuc) and the 
galectin-3 hairpins (Supplementary Fig. 6H), suggesting that galectin-3 production by the 
metastases does not affect colonization. Thus, any interactions with galectin-3 that promote 
metastasis likely result from its expression by stromal populations.
Based on the observation that galectin-3-deficient tumors are still capable of inducing 
myeloid cell mobilization into circulation, we investigated whether other tumor-derived 
factors might elicit this mobilization. We next asked whether the tumors produce other 
cytokines or chemokines that may recruit the leukocytes. Analysis of the CM by Luminex 
ELISA revealed elevated levels of interleukin 6 (IL-6) compared to control medium (Fig. 
3C). IL-6 is a pleotropic cytokine known to act upon multiple leukocyte subsets. As the 
TnonMet line also elicited myeloid cell mobilization, we examined Il6 gene expression levels 
in all of the cell lines from each of the four groups (Fig. 3D). Analysis of gene expression 
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microarray data revealed constant expression of Il6 across all four classes of cell lines, 
suggesting that expression of IL-6 by tumors commences early in tumorigenesis.
To determine the relevance of tumor-derived IL-6 to the human disease, we examined 
genomic amplification of the IL6 gene in patients with lung adenocarcinomas. Compared to 
normal blood or lung, lung adenocarcinomas had significantly elevated copy numbers of the 
IL6 gene (Fig. 3E, P = 5.04 × 10−27). Thus, we asked whether IL-6 induces the mobilization 
of the galectin-3+ leukocytes in our system. In contrast to galectin-3, injections of 
recombinant IL-6 induced the rapid mobilization of CD11b+galectin-3+ leukocytes and the 
relevant subpopulations into the circulation in a manner that mirrored CM injections (Fig. 
3F,G and Supplementary Fig. 7A–D). To identify the set of leukocytes responsible for 
galectin-3 presentation, we analyzed the granulocytes, as they may represent a large portion 
of the mobilized CD11b+Gr-1+ cells. Thus, we repeated the IL-6 experiments in Csf3r (G-
CSF-R) knockout mice, which exhibit impaired granulocyte production and maturation. 
While IL-6 was still capable of inducing CD11b+Ly-6Chi cell mobilization, Csf3r−/− mice 
exhibited a profound reduction in CD11b+galectin-3+ and CD11b+Gr-1+ leukocytes 
compared to wild-type mice (Supplementary Fig. 8A–D). These findings suggest that tumor-
derived IL-6 is sufficient to induce mobilization of galectin-3+ leukocytes.
To determine whether galectin-3 expression by the myeloid cells or another non-
parenchymal population is a prerequisite to their mobilization into circulation, we repeated 
the IL-6 injections in Lgals3 (galectin-3) knockout mice and observed no differences in 
CD11b+ myeloid cell mobilization compared to wild-type mice (Fig. 3H and Supplementary 
Fig. 9A–E). The relevant subpopulations also demonstrated similar mobilization 
(Supplementary Fig. 9A–D). Taken together these data suggest that IL-6, and not galectin-3, 
acts systemically as a factor to induce the mobilization of CD11b+galectin-3+ leukocytes 
from the bone marrow and that display of galectin-3 by the BMDCs is not a prerequisite to 
their mobilization.
Increasingly metastatic cells exhibit elevated T-Antigen surface presentation that mediates 
galectin-3 binding
Our previous studies demonstrated that cells increase their adhesion to galectin-3 as they 
gain metastatic potential (30). In light of the enrichment of galectin-3+ leukocytes in the 
peripheral blood (Fig. 2) and metastatic niche (Fig. 1D), we asked how the metastatic 
populations achieve enhanced adhesion to galectin-3. As galectins bind β-galactoside 
glycans through their carbohydrate recognition domain (CRD), we asked whether changes in 
glycan presentation by tumor cells confer their adhesion to galectin-3 on recruited 
leukocytes during metastasis. Analysis of glycan microarray datasets (35) and existing 
literature reveal a variety of carbohydrate ligands for these galectins (Fig. 4A). While all 
galectins bind lactosamines, galectin-3 exhibits specific affinities for the Thomsen-
Friedenreich Antigen (T-Antigen, Galβ1-3GalNAcα1-Ser/Thr), a pan-carcinoma marker 
expressed on many glycoproteins (Fig. 4B) (36). Galectin-3 is unable to interact with the T-
Antigen if the disaccharide is further glycosylated. Thus, we asked whether metastatic cells 
exhibit elevated T-Antigen levels on their surfaces that might mediate interactions with 
galectin-3. Staining of TnonMet, TMet, and M lines with a T-Antigen-specific lectin, peanut 
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agglutinin (PNA), revealed that the levels of T-Antigen surface presentation (~20 fold 
increase) correlate with metastatic potential (Fig. 4C and Supplementary Fig. 10A). To 
determine whether metastatic cell adhesion to galectin-3 is indeed carbohydrate mediated, 
we incubated the cells with fluorescent galectin-3 in the presence of a competitive binder, N-
Acetyllactosamine (LacNAc). Flow cytometry revealed a reduction in binding in the 
presence of LacNAc compared to control (sucrose), suggesting that galectin-3 adhesion to 
the metastatic cells is carbohydrate mediated (Fig. 4D).
To investigate whether these alterations are observed in the human disease, we stained 
human NSCLC tissue microarrays of 100 tissue samples with PNA to assess the presence of 
the T-Antigen. This staining revealed elevated levels of cell-surface T-Antigen presentation 
in cancerous tissue compared to non-cancerous tissue, with a notable enrichment in the 
lymph node metastases (Fig. 4E,F and Supplementary Fig. 10B). Additionally, we examined 
four common NSCLC cell lines for their relative expression of the T-Antigen. Flow 
cytometry revealed that, indeed, three of the four lines bound PNA at comparable levels to 
the M line, with the most invasive of the lines, A549 (37), exhibiting the highest degree of 
staining (Fig. 4G). Taken together, these data suggest that lung tumors bind galectin-3 
through carbohydrate epitopes, such as the T-Antigen, and that this epitope is expressed 
more highly on metastatic cells.
Differential gycosyltransferase expression promotes increased T-Antigen presentation 
through reduction of glycan chain elongation and increased capping
A variety of O-linked glycoproteins, such as MUC1, can exhibit profound degrees of O-
glycosylation, and differential regulation of such glycoproteins can significantly alter the 
overall glycan presentation of cells. Thus, we asked whether increased T-Antigen expression 
is a result of upregulation of individual glycoproteins or altered glycosyltransferase activity. 
We isolated cell membrane proteins from TnonMet, TMet, and M lines and performed PNA 
lectin blots. These revealed a global increase in T-Antigen expression across many 
glycoproteins in the increasingly metastatic cells, as opposed to PNA labeling of a specific 
glycoprotein (Fig. 5A).
In light of this broad distribution in glycosylation, we investigated alterations in the 
expression and activity of glycosyltransferases. Analysis of gene expression microarrays for 
216 glycosyltransferase genes did not demonstrate widespread shifts in expression, nor were 
there significant changes in the subset of genes that encode transferases specific for 
generation of the galectin-3 ligands (Supplementary Fig. 11A, B). Comparisons between the 
averages for the primary tumor and metastasis-derived cell lines, however, identified Gcnt3 
and St6galnac4 as being under- and over-expressed in the metastatic lines, respectively (Fig. 
5B); these alterations were confirmed by qRT-PCR in the representative cell lines (Fig. 5C, 
top). C2GnT2 (Gcnt3) induces the addition of a β(1-6)GlcNAc to the T-Antigen, whereas 
St6GalNAcIV adds an α(2-6)NeuAc to the sialyl-T-Antigen (Fig. 5C, bottom). As further 
elongation of the core 1 disaccharide prevents binding by galectin-3 (Fig. 4B), changes in 
transferase activity consistent with the expression changes in Gcnt3 and St6galnac4 would 
promote T-Antigen presentation through prevention of branching and capping of elongation, 
respectively. Gene expression microarray analysis of the other cell lines of each class 
Reticker-Flynn and Bhatia Page 7
Cancer Discov. Author manuscript; available in PMC 2015 August 01.
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
revealed similar trends for these and analogous transferases (Supplementary Fig. 12). 
Consistent with the fact that generation of the T-Antigen occurs in the Golgi prior to 
subsequent glycosylation (38), no difference in T-Antigen blotting was visible between 
whole cell lysates of TMet and M lines (Supplementary Fig. 13A), further confirming that 
differences in its presentation are due to decreased glycan extension rather than increased 
production of the disaccharide.
To determine the relevance of the capping and branching transferases to human disease, we 
again examined copy number of the GCNT3 gene in the human TCGA lung cancer datasets. 
This analysis revealed a decrease in copy number in lung adenocarcinoma compared to 
normal blood or lung (Fig. 5D, P = 1.44 × 10−11). Additionally, we examined gene 
expression of the relevant glycosyltransferase genes in the four human NSCLC cell lines 
that exhibited varying degrees of PNA staining. While minimal differences in expression 
were observed for the transferases that give rise to the core disaccharide (C1GALT1 and 
C1GALT1C1), there were marked variances across the lines for the genes encoding 
transferases that produce the branched and capped structures (Supplementary Fig. 13B). 
These data suggest that alterations in glycosyltransferase activity that regulate capping or 
branching of the T-Antigen may also pertain to the human disease.
Regulation of Gcnt3 and St6galnac4 mediate galectin-3 adhesion in vitro and metastasis in 
vivo
To test the functional role of these transferases on galectin-3 binding and metastasis, we 
transfected the metastatic cells with Gcnt3 or knocked down St6galnac4 with short hairpins. 
Transfection of Gcnt3 resulted in decreased T-Antigen presentation and decreased galectin-3 
binding, and, in a complementary fashion, knockdown of St6galnac4 yielded a reduction in 
galectin-3 binding, while having no effect on non-sialylated T-Antigen presentation (as PNA 
does not recognize sialylated forms of the antigen) (Fig. 6A and Supplementary Fig. 14A–E, 
15A, B). To determine the functional role of St6GalNAcIV activity on metastasis in vivo, we 
performed experimental metastasis assays with the St6galnac4 knockdown line. Cells 
expressing a hairpin for the sialyltransferase or a control hairpin against firefly luciferase 
were injected into the spleens of mice and monitored for liver tumor formation following 
hematogenous dissemination. We found that mice injected with the 393M1-shSt6galnac4 
cells exhibited greater than 95% fewer liver metastases than control mice two weeks 
following tumor cell injection (Fig. 6B,C and Supplementary Fig. 16). We observed no 
differences in proliferation rates between the knockdown and control hairpin cell lines in 
vitro (Supplementary Fig. 17). Taken together, these data suggest that alterations in 
glycosyltransferase activity observed in increasingly metastatic cells have a functional 
impact on the metastatic potential of the tumor cells and support the hypothesis that 
presentation of the T-Antigen, through the prevention of further glycosylation, promotes 
adhesion of tumor cells to galectin-3 in the metastatic niche.
Discussion
A variety of molecules have been demonstrated to play important roles in colonization of the 
early metastatic niche through their systemic secretion and by interacting with recruited 
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CD11b+ leukocytes (14–19). The identification of direct interactions between these 
leukocytes and tumor cells within the blood vessels and colonized tissues suggests a role for 
a conserved adhesion receptor-ligand axis during metastatic progression. Here, we identify 
galectin-3 as a novel regulator of lung adenocarcinoma metastasis through its presentation 
within the metastatic niche and binding to the oncofetal disaccharide known as the T-
Antigen (Fig. 7). Based on our findings, we propose that early in tumorigenesis, tumors 
secrete soluble factors, such as IL-6, that induce the mobilization of CD11b+galectin-3+ 
BMDCs into circulation. Additionally, galectin-3 is presented on macrophages in the early 
metastatic niche of tumor-bearing mice. As tumors gain metastatic potential, they increase 
their presentation of the T-Antigen on their surfaces. In the context of our lung 
adenocarcinoma mouse model, we show that this elevated presentation does not result from 
increased O-glycosylation through core 1 glycosyltransferases, but rather is due to the 
abrogation of core 1 chain extension conferred by downregulation of C2GnT2 and capping 
of the motif by the α2-6 sialyltransferase St6GalNAcIV. These changes in transferase 
activity and T-Antigen presentation result in increased carbohydrate-dependent binding of 
the tumor cells to galectin-3 and increased metastasis in vivo. As the presence of tumors 
induces elevated numbers of galectin-3+ myeloid cells in the circulation and metastatic 
niche, these alterations in transferase activity within the tumor cells may represent an 
essential mechanism by which metastatic cells interact with these pro-tumorigenic 
leukocytes at those sites. Furthermore, perturbations in expression of these transferases are 
correlated with humans with NSCLC (Fig. 5 and Supplementary Fig. 13B), and the T-
Antigen is frequently overexpressed on many cancers (36), suggesting that this model of 
glycan regulation may extend to many clinical settings.
Dissemination of tumor cells is thought to occur early in tumorigenesis (39). Recent 
evidence supports the concept that the rate-limiting step in the formation of clinically-
relevant tumors is the adaptation of disseminated cancer cells to their local 
microenvironments in a manner that permits colonization (11). Additional studies have 
suggested that early, or even “pre-”, metastatic niches may exist wherein a protumorigenic 
microenvironment is generated (12). Such microenvironments harbor inflammatory 
leukocytes that act to promote metastatic colonization (11, 13, 40). Our findings on the 
mobilization and recruitment of these inflammatory populations by nonmetastatic primary 
tumors are consistent with the hypothesis that involvement of pro-metastatic stromal 
populations is, at least in-part, an early event. Thus, adaptations by the metastatic tumor 
cells that potentiate interactions with these leukocytes may represent the rate-limiting events 
permitting colonization. Here, we find that alterations in glycosylation that result in T-
Antigen presentation is one such event in that it occurs later in tumor progression and 
promotes interactions with galectin-3 in the metastatic niche.
A variety of studies have implicated galectin-3 in tumor progression and metastasis (1). The 
majority of these studies have demonstrated strong clinical correlations with advanced stage 
disease or decreased survival with elevated levels of galectin-3 (4, 5). In agreement with 
these clinical reports, our model also demonstrated elevated serum levels of galectin-3 in 
mice bearing tumors (Supplementary Fig. 18). Experimental studies have primarily 
investigated the roles of galectins in modulating the immune system (3) or in interactions 
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with blood vessels. In addition to its reported role in promoting angiogenesis (41), surface 
expression of galectin-3 on endothelial cells has been suggested to promote adhesion of 
breast and prostate cancer cells to the endothelium through carbohydrate interactions (7). 
Here, we suggest an additional role for galectin-3 in metastasis in that it is presented within 
the early metastatic niche on recruited metastasis-associated myeloid cells. Thus, galectin-3 
may not act only to promote adhesion to endothelium, but also to promote interactions 
between the cancer cells and BMDCs within the tissues or within circulation in a manner 
that not only promotes extravasation but also colonization.
An abundance of clinical and experimental evidence has suggested a role for interleukin 6 
(IL-6) in cancer metastasis (19, 21, 42–44). Tumor-derived soluble factors, including a 
variety of ECM molecules such as laminins and versican (19), have been reported to act 
upon macrophages, through Toll-like receptors (TLRs), to induce the production of IL-6. 
Here, we find that lung tumors, themselves, produce IL-6 independent of the presence of the 
myeloid cells. Our conditioned medium experiments suggest that soluble factors such as 
IL-6 are capable of inducing the rapid mobilization of CD11b+Ly6Chi and CD11b+Gr-1+ 
myeloid cells into circulation, which are thought to promote metastasis. Other molecules 
traditionally considered to be produced by myeloid cells, such as CCL2, can be produced by 
tumor cells to induce the recruitment of pro-metastatic CD11b+ populations (25). The 
production of cytokines, such as IL-6, by tumors represents another means by which tumors 
can indirectly promote the development of inflammatory microenvironments at distant sites.
Alterations in glycosylation have long been associated with malignancy (45–47). Many 
clinical biomarkers are carbohydrate antigens such as CA19-9, CA125, DUPAN-II, and 
AFP-L3 (48). Furthermore, overexpression of many O-linked glycoproteins, such as MUC1, 
have been correlated with malignancy (49). As a result, this glycoprotein has been the 
subject of numerous vaccine development initiatives, and these vaccines are typically more 
efficacious when the glycosylated antigen is used (49, 50). In addition to expression of 
particular glycoproteins, aberrant glycosyltransferase activity is frequently observed in a 
variety of cancers. We show that upregulation of St6GalNAcIV and downregulation 
C2GnT2 preserve presentation of the T-Antigen through prevention of O-glycan chain 
elongation. Together with previous findings of overexpression of ST6GALNAC5 in breast 
cancer metastasis to the brain (24) and general increases in sialylation on metastatic cell 
lines(51), our study suggests a conserved mechanism by which the T-Antigen is presented 
on metastasizing cells that appears to potentiate colonization through interactions with 
galectins in the metastatic niche. It is worth noting that a recent study found that another 
sialyltransferase, ST6GalNAcII, may influence metastatic potential (52). In this case, 
however, knockdown of ST6GalNAcII in a breast cancer cell line led to an increase in 
metastasis. While, on the surface, this finding appears to contradict those presented within 
this manuscript, the data are consistent in that in both cases, glycosylation-dependent 
galectin-3 binding promotes metastasis formation. One possibility is that the inverse 
regulation of the two transferases may result in the same functional phenotype, with 
ST6GalNAcII preventing presentation of the galectin-3 ligand N-Acetyllactosamine or 
similar ligands, and ST6GalNAcIV promoting expression of the T-Antigen. Previously, we 
found that the integrin α3β1 promotes metastasis through binding to combinations of 
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fibronectin with either galectin-3 or -8 (30). Integrins contain a variety of glycosylation 
sites, and these data may suggest that glycosylation of integrins could promote metastasis 
through synergistic interactions between galectins and other ECM molecules within the 
metastatic niche. Regardless of the particular proteins exhibiting these glycosylation 
patterns, our observations of alterations in transferase expression and T-Antigen presentation 
in humans with the disease suggests a role for a highly conserved mechanism of glycan-
mediated lung cancer metastasis that warrants consideration for therapeutic intervention.
Methods
Cell Lines and Mouse Transplantation Assays
Murine cell lines (a gift from Tyler Jacks and Monte Winslow, Massachusetts Institute of 
Technology, Cambridge, MA) were described previously (28) and were cultured in DMEM 
with 10% (vol/vol) fetal bovine serum and 1% L-glutamine. The cell lines were used within 
five passages of the distributed vials and were tested frequently for consistency in gene 
expression by qRT-PCR. No additional authentication was performed. All cell lines were 
tested for pathogens by PCR by the MIT Division of Comparative Medicine during the time 
period in which they were being used. The human NSCLC lines were provided by the 
National Cancer Institute (NCI) through the Division of Cancer Treatment and Diagnosis 
(DCTD) Tumor Repository. The repository authenticates the lines and tests all cell lines for 
pathogens by PCR prior to distribution. Experiments were performed within five passages of 
the distributed vials.
All animal procedures were performed in accordance with the MIT Institutional Animal 
Care and Use Committee under protocol 0211-014-14. Cell injection studies were performed 
in female B6129SF1/J mice 6–10 weeks of age (Jackson Laboratory, Stock Number 
101043). Additionally, IL-6 experiments were performed in B6.129X1(Cg)-Csf3rtm1Link/J 
and B6.Cg-Lgals3tm1Poi/J mice (Jackson Laboratory, Stock Numbers 017838 and 006338) 
with C57BL/6J mice as controls (Jackson Laboratory, Stock Number 000664). For CD11b 
mobilization experiments, mice were injected with 3×105 cells resuspended in 100μL of 
PBS into the subcutaneous region of flanks of mice, while anesthetized with isofluorane. 
Tumors and peripheral blood were harvested 5–8 weeks following injections. 
Approximately 1mL of peripheral blood was harvested by cardiac puncture, while mice 
were anesthetized with isofluorane and used for analysis by flow cytometry. Mice were 
immediately euthanized following recovery of the blood and their tumors were harvested.
Intrasplenic transplantation assays were performed as previously described(30). Briefly, 
5×105 cells were resuspended in 100μL of phosphate buffered saline (PBS). Animals were 
anesthetized with 2.5% isofluorane and administered buprenorphine (150μg/kg). Fur was 
removed with surgical clippers and the incision site was sterilized with Betadine and 70% 
ethanol. The spleen was exposed through a small incision and cells were injected into the tip 
of the spleen with a 27-gauge needle. The cells were allowed to travel through circulation 
for two minutes prior to removal of the spleen. The splenic vessels were then cauterized and 
the entire spleen was removed. The muscle wall was closed with 5-0 dissolvable sutures, 
and the skin was closed with 7mm wound clips (Roboz). Mice were euthanized two weeks 
following injection, and their livers were excised. GFP+ tumors were visualized and 
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quantified using an epifluorescence dissection scope (Nikon). Tissues were fixed in 4% 
paraformaldehyde and stained with hematoxylin and eosin following paraffin embedding.
Immunohistochemical and Immunocytochemical Analysis
Following necropsy, tumors and livers were fixed overnight in 4% paraformaldehyde at 4°C. 
Tissues used for paraffin embedding were transferred to cassettes and placed in 70% 
ethanol. Those used for frozen sections were placed in 30% sucrose overnight at 4°C. 
Tissues were then transferred to O.C.T. compound (Tissue-Tek) for 4 hours at room 
temperature followed by freezing in isopentane (Sigma) placed in a liquid nitrogen bath. Co-
staining of galectin-3 and F4/80 was performed on frozen sections using antibody clones 
M3/38 (BioLegend) and CI:A3-1 (BioLegend), respectively. Nuclei were stained with 
Hoechst (Invitrogen). For studies of livers prior to the detection of overt metastases, excised 
tissues were examined grossly for the appearance of nodules and microscopically, following 
staining, for the presence of tumors.
For fluorescent lectin analysis of T-Antigen presentation, cells were stained with PNA-
AlexaFluor 647 (invitrogen). All paraffin sections were developed using DAB and 
counterstained with hematoxylin. Carbo-Free Blocking Solution (Vector Laboratories) was 
used for all staining involving the use of peanut agglutinin. Endogenous peroxidase activity 
was blocked using the Dual Endogenous Enzyme Block (Dako). PNA staining of human 
tissue microarrays was performed with PNA-HRP (Sigma, 4μg/mL) following antigen 
retrieval in citrate buffer. Staining of the Human Lung Cancer and Normal Tissue 
Microarray (US Biomax, Inc) was scored for the presence of surface T-Antigen staining in a 
blinded fashion.
All images were acquired using an inverted Nikon Ti-E epifluorescence microscope using 
Elements software (Nikon). Pseudocoloring was performed using Elements or ImageJ 
(NIH). Quantification of histology was performed using Elements.
Western and PNA Lectin Blot Analysis
Cell lysates were harvested in RIPA buffer (Sigma) containing Complete Protease Inhibitor 
(Roche) and Phospho Stop (Roche) on ice and run on SDS-PAGE gels. PVDF membranes 
were stained for galectin-3 (Abcam, ab53082, 1:500, or BioLegend, M3/38, 1:1000), 
galectin-8 (Abcam, ab69631, 1:500), and α-tubulin (Cell Signaling, 2125, 1:1000). Lectin 
blotting for glycans was performed using PNA-Biotin (Sigma) followed by detection using 
the ABC Elite Kit (Vector Labs, PK-6100) or PNA-Peroxidase conjugates (Sigma). Ponceau 
S solution (Thermo) was used for total protein detection following transfer to PVDF 
membranes.
For liver homogenate western blots, mice bearing 393M1 flank tumors or no tumors were 
perfused by intracardiac injection of 20mL of phosphate buffered saline. Livers were then 
excised and 50mg portions were added to gentleMACS M tubes (Miltenyi Biotech) in 
4.5mL of RIPA (Sigma) with Complete Protease Inhibitors (Roche). Tissue was dissociated 
using the gentleMACS Octo Dissociator (Miltenyi Biotech) and run on polyacrylamide gels 
as described above.
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Galectin-3 ELISA
Peripheral blood was harvested from mice without tumors or bearing contralateral flank 
tumors of both 802T4 and 393T5 cell lines by cardiac puncture as described above. Blood 
was collected in serum collection tubes (Capiject) and allowed to clot for 30 minutes prior to 
centrifugation and removal of serum. The galectin-3 ELISA kit (R&D Systems) was used 
according to the manufacturer’s instructions.
Cell Surface Protein Isolation
Cell surface proteins were isolated prior to Western blot analysis using Thermo Scientific kit 
89881 following the manufacturer’s instructions. Briefly, cells are washed followed by 
biotinylation of the surface proteins by a Sulfo-NHS-Biotin through conjugation to free 
amines. The reaction is quenched and cells are harvested and lysed. Lysate is washed 
through a column containing a neutravidin resin to capture the biotinylated surface proteins. 
Finally, the disulfide linkage is reduced through incubation with 50mM DTT and the 
proteins are captured.
Flow Cytometric Analysis
Peripheral blood was drawn by cardiac puncture and transferred to K2 EDTA 5.4mg Plus 
Blood Collection Tubes (BD Vacutainer, BD Biosciences). Red blood cells were lysed using 
RBC lysis buffer (eBiosciences). Cells were fixed in 4% paraformaldehyde and washed 
prior to staining. Cells were blocked using anti-mouse CD16/CD32 antibody clone 2.4G2 
(BD Biosciences). Antibodies against mouse antigens were: CD11b (M1/70, BD 
Biosciences), CD115 (AFS98, eBiosciences), Mac-2 (M3/38, BioLegend), Ly-6C (HK1.4, 
BioLegend), and Gr-1 (RB6-8C6, BioLegend). Flow cytometry was performed on a LSR 
Fortessa (BD Biosciences) and analyzed using Flowjo (Tree Star).
Magnetic separation of CD11b+ cells was performed using CD11b MACS microbeads 
(Miltenyi). Following collection of peripheral blood by cardiac puncture and lysis of 
erythrocytes, cells were incubated with the MACS beads following the manufacturer’s 
instructions. CD11b+ cells were isolated using MACS MS Collection Columns (Miltenyi).
Peanut agglutinin staining was performed by incubating 3×105 cells in PBS with 10μL 
PNA-AlexaFluor 647 (invitrogen) on ice for 30 minutes. Fluorescent galectin-3 was 
produced by reacting recombinant murine galectin-3 (R&D Systems) with DyLight 650 
NHS Ester (Thermo Pierce). Conjugated protein was purified by FPLC and concentrated to 
0.5mg/mL using 3,000 MWCO Amicon centrifugal filter units (Millipore). Cells were 
stained by incubating 3×105 cells in PBS with 10μL of the fluorescent galectin-3 on ice for 
30 minutes.
For galectin-3 binding inhibition experiments on tumor cells, cells were incubated with 
galectin-3, as described above in the presence of 20mM N-Acetyl-D-lactosamine 
(Carbosynth) or sucrose (Sigma). For competition of galectin-3 presentation on leukocytes, 
peripheral blood was harvested from mice bearing 393M1 flank tumors, as described above. 
Cells were incubated with 200mM β-lactose (Sigma) or sucrose (Sigma) in 2% FBS for 30 
minutes on ice. Cells were then fixed, stained, and analyzed by flow cytometry.
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Conditioned Media Experiments
Twenty-five milliliters of conditioned medium was harvested from one T150 flask of 
393M1s following three days of culture. This medium (or fresh control medium with serum) 
was filtered through 0.2μm filters and concentrated 15-fold using 3,000 MWCO centrifugal 
filters (Amicon). 200μL of medium was injected into the lateral tail vein of mice. Two hours 
after injections, peripheral blood was harvested from the mice by cardiac puncture, as 
described above, followed by fixation, staining, and flow cytometric analysis. For 
experiments involving recombinant galectin-3, murine recombinant galectin-3 (R&D 
Systems) was supplemented to the medium at 1μg per injection. For IL-6 experiments, 
murine recombinant IL-6 (R&D Systems) was supplemented to the medium at 50ng per 
injection.
Luminex Cytokine Profiling
Cytokine profiles of 100uL cell culture supernatant from control and conditioned media 
were assessed using a EMD Millipore Milliplex custom magnetic bead panel using 
manufacturer’s protocol: IL-2, IFNg, IL-10, TNFa, IL-17a, IL-4, IL-5, IL-6. Luminex assays 
were analyzed using Bioplex 200 with Bioplex Manager 6.1.
RNA Isolation and Expression Profiling
Murine gene expression microarray analysis was described previously(28, 30) and is 
available from NCBI under accession number GSE40222 and GSE26874. Human NSCLC 
expression microarray data was accessed from NCBI accession number GSE32474. RNA 
was isolated using RNeasy mini kits (Qiagen) according to the manufacturer’s instructions. 
cDNA reactions were performed using iScript cDNA synthesis kit (Bio-Rad). qPCR 
reactions were performed using 2μL of cDNA, 12.5μL of IQ SYBR Green Supermix (Bio-
Rad), and 1μmol of each primer. Fold change is reported following analysis using the ΔΔCt 
method where genes were normalized to Hprt housekeeping control. Primers were: 
St6galnac4 forward 5′-GGTTGGTTCACCATGATTCTG-3′, St6galnac4 reverse 5′-
GGAGCGGGGACTCTTCTC-3′, Gcnt3 forward 5′-GCAGCCAAGAAGGTACCAAA-3′, 
Gcnt3 reverse 5′-ACAGGCGAGGACCATCAA-3′ or forward 5′-
ATGAGAGCCATTGCGAGACT-3′ reverse 5′-CTTGTTGGCCAAGAGGTGAT-3′, Hprt 
forward 5′-GTCAACGGGGGACATAAAAG-3′, Hprt reverse 5′-
CAACAATCAAGACATTCTTTACA-3′. Gene expression analysis and visualizations were 
performed using Spotfire (Tibco) and MATLAB (Mathworks).
Human Copy Number Analysis
Copy number determinations of GCNT3 and IL6 were performed using Oncomine (53) 
based on publicly-available data from the Cancer Genome Atlas (54).
Hairpins and Plasmids
Knockdown of St6galnac4 was performed using short-hairpin RNA (5′-
TTCTGCTCCTCACACTGTGCATCTTGACA-3′) or a control hairpin targeting firefly 
luciferase in the pGFP-V-RS vector (Origene, TG502032 and TR30002). Plasmids were 
packaged into retroviruses using the Phoenix-Eco system. Viral supernatant was filtered 
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using 0.45μm syringe filters and cultured with 393M1 cells at no dilution. Transduced cells 
were selected with puromycin (Invitrogen), and knockdown efficiency was determined by 
qRT-PCR following four weeks of culture. Tansfection of Gcnt3 was performed using 
Lipofectamine (Invitrogen) according to the manufacturer’s instructions with plasmids 
purchased from Origene (MC215765). Knockdown of Lgals3 was performed using two 
short-hairpin RNAs (Sigma, shGal3-3: 5′-
CCGGGCAGTACAACCATCGGATGAACTCGAGTTCATCCGATGGTTGTACTGCTT
TTT G-3′; shGal3-5: 5′-
CCGGCCGCATGCTGATCACAATCATCTCGAGATGATTGTGATCAGCATGCGGTT
TTT G-3′) or a control hairpin targeting firefly luciferase in (Sigma, SHC007V). 
Additionally, a second hairpin system was used to knockdown St6galnac4 from Sigma 
(shSt6galnac4-2: 
CCGGGTACACCTTCACTGAACGCATCTCGAGATGCGTTCAGTGAAGGTGTACTT
TTT G).
In vitro Proliferation Assays
Cells expressing hairpins against St6galnac4 or control hairpins were seeded into 24-well 
plates. New wells were trypsinized and counted using a hemocytometer with Trypan Blue 
exclusion at 24 hour intervals.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Significance
While clinical observations of elevated serum galectin-3 levels and altered glycosylation 
have been associated with malignancy, we identify novel roles for glycosyltransferases in 
promoting adhesion to galectins in the metastatic niche. This identification of a cytokine-
leukocyte-glycosylation axis in metastasis provides mechanistic explanations for clinical 
associations between malignancy and aberrant glycosylation.
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Figure 1. Mice bearing tumors have accumulation of the adhesion ligand, galectin-3, in the early 
metastatic niche
(A) Cell lines are generated from autochthonous tumors in KrasLSL-G12D/+;p53flox/flox mice 
following tumor development. The lines, which represent discrete stages of metastasis, are 
derived from primary tumors that did not metastasize (TnonMet), primary tumors that gave 
rise to metastases (TMet), lymph node metastases (N, not shown), and distant metastases 
(M). Lines derived from increasingly metastatic tumors exhibit increased adhesion to 
galectin-3 and galectin-8. (B) Mice bearing the no tumors, TnonMet, and M tumors were 
analyzed for the presence of galectin-3 in their livers prior to the detection of overt 
metastases. Mice were perfused with saline prior to homogenization of liver tissue and 
analysis by western blot. (C) Left: Immunostaining of livers from mice bearing M tumors 
with no detectable overt metastases in their livers for the presence of macrophages (F4/80, 
green) and galectin-3 (pink). Nuclei (blue) are stained with Hoechst. Dashed boxes in the 
top row highlight the area shown in the bottom row. Scale bars in (C) are 50μm (top) and 
25μm (bottom). Right: Quantification of galectin-3posF4/80pos cells in the livers of mice 
without tumors, TnonMet tumors, or M tumors. Error bars are s.e.m. P-values in (C) were 
determined by One-way ANOVA with Tukey’s Multiple Comparison Test. * P < 0.05; *** 
P < 0.001.
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Figure 2. Tumor-derived soluble factors induce the mobilization of galectin-3+ myeloid cells into 
peripheral circulation early in tumorigenesis
Wild-type mice or mice bearing TnonMet (802T4) or M (393M1) tumors were analyzed for 
the presence of galectin-3+ leukocytes in their peripheral blood by flow cytometry. (A) 
Analysis of staining for galectin-3 and CD11b on all leukocytes from mice without tumors 
(NT), TnonMet tumors, or M tumors. Numbers represent percentages of all leukocytes that 
were double positive. (B) Percentage of all leukocytes that were galectin-3+. (C) Percentage 
of all cells that were CD11b+. (D) Percentage of all cells that were CD11b+galectin-3+. (E) 
Percentage of all leukocytes that were Gr-1+. (F) Ratio of CD11b+Ly-6Chi cells to 
CD11b+Ly-6Clo cells. (G) Galectin-3 expression on Ly-6Clo and Ly-6Chi cells. P-values in 
(B-F) were determined by One-way ANOVA with Tukey’s Multiple Comparison Test. P-
values in (G) were determined by Two-way ANOVA with Bonferroni post-test. * P < 0.05; 
** P < 0.01; *** P < 0.001.
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Figure 3. Secretion of IL-6 by tumors induces the rapid mobilization of CD11b+galectin-3+ 
leukocytes
(A) Analysis of CD11b+galectin-3+ myeloid cell mobilization to peripheral blood following 
injections of control medium (white), M line conditioned medium (red), or recombinant 
murine galectin-3 supplemented control medium (gray). (B) Analysis of CD11b+galectin-3+ 
myeloid cell mobilization following injections of conditioned media from M lines 
containing either a control hairpin (shLuc, black) or galectin-3 hairpins (red). (C) Luminex 
cytokine levels of the conditioned medium. (D) Gene expression microarray analysis of Il6 
expression in all cell lines from the four classes. (E) IL6 exhibits a gain of copy number in 
human lung adenocarcinomas compared to normal lung tissue or blood (P = 5.04 × 10−27) in 
the “Lung adenocarcinoma” data set available from The Cancer Genome Atlas website (see 
Methods). (F,G) Analysis of CD11b+galectin-3+ cell mobilization to peripheral blood 
following injections of control medium or medium supplemented with recombinant murine 
IL-6. (H) Mobilization of CD11b+ leukocytes in wild-type and galectin-3 knockout 
(Lgals3−/−) mice following IL-6 injections. Error bars in (C) are s.e.m. ‘N.D.’: not detected. 
P-values in (A) and (H) were calculated by One-way ANOVA with Tukey’s Multiple 
Comparison Test. P-value in (G) determined by Student’s t-test. *** P < 0.001; ‘n.s.’ not 
significant.
Reticker-Flynn and Bhatia Page 22
Cancer Discov. Author manuscript; available in PMC 2015 August 01.
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
Figure 4. Elevated Thomsen-Friedenreich Antigen presentation promotes increased galectin-3 
adhesion in metastatic populations
(A) Potential carbohydrate ligands for the galectin-3 carbohydrate recognition domain 
(CRD). The T-Antigen (Galβ1-3GalNac-α1-O-S/T) is specific for the CRD of galectin-3 and 
-8. N-Acetyllactosamine (LacNAc) binds the CRD of all galectins and exhibits increased 
affinities when in a polymeric form. The A- B- Type 2 blood group antigens have reported 
affinities for a variety of galectins, including galectin-3, by glycan array analysis (35). (B) 
On normal cells binding of galectin-3 to the T-Antigen on glycoproteins is occluded as the 
epitope is masked by further glycan extension. On malignant cells, abberant expression of 
the disaccharide without further glycosylation permits galectin-3 binding. (C) Peanut 
agglutinin (PNA) labeling of the T-Antigen on representative cell lines from the TnonMet 
(blue), TMet (green), and M (red) classes as determined by flow cytometry. (D) Binding of 
galectin-3 fluorophore conjugates in the presence of a glycan competitor for galectin-3, N-
acetyllactosamine (LacNAc), or control disaccharide (sucrose). (E–F) Human NSCLC tissue 
microarrays were analyzed for surface T-Antigen presentation by PNA staining. (E) Sample 
tissue staining in lung and lymph node tissue. Examples of tissues scored as PNAneg and 
PNApos are shown. (F) Quantification of TMA spots for PNA staining: ‘N’: non-cancerous 
tissue; ‘C’: cancer tissue. (G) PNA labeling of human NSCLC cell lines as determined by 
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flow cytometry. P-values in (F) determined by Fisher’s Exact Test. Scale bars in (E) are 
400μm (100μm for insets).
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Figure 5. Metastatic cells downregulateGcnt3 and upregulate St6galnac4
(A) Lectin blot of surface proteins. Cell surface proteins were isolated from representative 
TnonMet (802T4), TMet (393T5), and M (393M1) lines and run on SDS-PAGE gels. 
Membranes were blotted for the T-Antigen with PNA. (B) Gene expression microarray 
analysis of all glycosyltansferases. The average expression for all primary tumor-derived 
lines (ordinate) is plotted against the average expression for all metastatic lines (abscissa). 
Size of points represents the absolute difference in expression between the clonally-related 
TMet and M lines (393T5 and 393M1, respectively). The color represents statistical 
significance of the differences between any two adjacent cell line classes (i.e. TnonMet vs. 
TMet, TMet vs. N, N vs. M) as determined by Student’s t-test. The dashed line represents 
equivalent expression between the metastatic and primary tumor-derived lines. (C) qRT-
PCR analysis of transferase gene expression. Top: gene expression of Gcnt3 and St6galnac4 
in representative TnonMet, TMet, and M cell lines. Bottom: C2GnT2 (Gcnt3) can transfer a 
GlcNAc to the core GalNAc of T-Antigen by a β1-6 linkage. St6galnac4 can transfer a 
NeuAc to the core GalNAc of the sialyl-T-Antigen. (D) GCNT3 exhibits a loss of copy 
number in human lung adenocarcinomas compared to normal lung tissue or blood (P = 1.44 
× 10−11) in the “Lung adenocarcinoma” data set available from The Cancer Genome Atlas 
website (54). P-values in (C) were determined by One-way ANOVA with Tukey’s Multiple 
Comparison Test. * P < 0.05; ** P < 0.01; *** P < 0.001.
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Figure 6. Knockdown of St6galnac4 reduces galectin-3 binding and prevents metastasis in vivo
(A) Analysis of galectin-3 binding to the M line 393M1 following knockdown of St6galnac4 
by retroviral transduction of short hairpins targeting St6galnac4 or a control gene (Luc, 
firefly luciferase) by flow cytometry. (E,F) Wild-type mice were transplanted with GFP+ M 
cells bearing the short hairpin targeting St6galnac4 (393M1-shSt6galnac4) or control hairpin 
(393M1-shLuc) by intrasplenic injection. Two weeks following implantation, the livers of 
mice were excised and imaged. (B) Representative livers as visualized by fluorescence (top), 
brightfield (middle), and hematoxylin and eosin staining (bottom). (C) Quantification of the 
number of surface nodules on the livers. Scale bars in (B) are 2mm. P-value in (C) was 
determined by Mann-Whitney test. ** P < 0.01.
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Figure 7. T-Antigen presentation promotes metastasis through interactions with galectins in the 
metastatic niche
Schematic model of galectin-glycan interactions in lung cancer metastasis. Primary lung 
tumors have high expression of branching glycosyltransferases such as C2GnT2 (Gcnt3) and 
low expression sialyltransferases such as St6GalNAcIV that act to promote O-glycan 
branching and elongation. Both the primary and metastatic tumors secrete tumor-derived 
soluble factors, such as IL-6, which act to mobilize CD11b+galectin-3+ myeloid cells into 
the peripheral blood. Galectin-3 levels become elevated in the liver early metastatic niche 
where it is presented on macrophages. Metastatic cells adhere to galectin-3 and -8 through 
increased T-Antigen presentation, which is mediated by aberrant glycosyltansferase activity. 
Decreased expression of the branching transferases and increased expression of 
sialyltransferases prevent glycan elongation and promote preservation of the T-Antigen, 
which in turn, mediates galectin-3 adhesion.
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